Executive Series - Bionomics (BNO) CEO & Managing Director, Deborah Rathjen
Tom Piotrowski speaks with Bionomics (BNO) CEO & Managing Director, Deborah Rathjen about clinical trial results of its anxiety drug BNC210 and its Phase 2 trial for managing Post Traumatic Stress Disorder (PTSD) To view more Executive Series interviews, visit: (VIEW LINK)
5 topics
most popular
Equities
The Indian companies dominating emerging market returns
Sara Allen,
Livewire Markets